FDA
-
-
-
-
-
-
-
Clene secures FDA meeting to discuss ALS drug biomarker data
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Clene, Inc. (CLNN)
-
-
-
-
-
-
-
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
-
-
-
-
-
-
-
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
-
-
-
-
-
-
-
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
-
-
-
-
-
-
-
Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility
-
-
-
-
-
-
-
Clene (CLNN) Announces New CNM-Au8 Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS
-
325,552 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

